Replimune co-founder calls FDA rejection of melanoma drug ‘unfair’

Summary

Philip Astley-Sparke, co-founder of Replimune, discusses the FDA's rejection of their melanoma drug on 'Squawk on the Street'. He argues that the rejection was unfair due to strong clinical data and support from the medical community. The company plans to continue pursuing approval, emphasizing the drug's potential for late-stage melanoma patients.

• Replimune's melanoma drug was rejected by the FDA despite showing a 34% remission rate in clinical trials.
• Co-founder Philip Astley-Sparke claims the rejection was unfair and cites methodological disagreements with the FDA.
• He highlights durable responses and resensitization to anti-PD-1 therapy as key efficacy points.
• There is strong support from oncologists and patient advocacy groups for the drug's approval.
• The interview focuses on the company's defense of the drug and next steps for regulatory approval.
• No explicit investment recommendations are made, but the company's prospects are discussed.
• The broader immunotherapy space is mentioned as being impacted by this decision.
• The discussion centers on clinical data and regulatory processes rather than financial performance.